NanoBio to present data from preclinical studies at 8th Annual International RSV Symposium

NanoBio® Corporation announced today it will present data from three preclinical studies at the 8th Annual International Respiratory Syncytial Virus (RSV) Symposium taking place from Sept. 27-30 in Santa Fe, N.M.    

The following presentations will occur on Friday, Sept. 28 at 9:30 - 10:30 a.m. Mountain Time:

Poster Presentation 51: "Whole virus RSV vaccine induced protective immunity with reduced lung histopathology compared to recombinant F protein RSV vaccine."

Poster Presentation 49: "Intranasal and Intramuscular Routes of RSV Vaccine Administration Serve to Highlight the Role of Th2 and Th17 in a Mouse RSV Challenge Model."

Poster Presentation 45: "Immunogenicity and efficacy of Line 19 RSV vaccine in cotton rats."

During the presentations, NanoBio will share preclinical data on its nanoemulsion adjuvanted intranasal RSV vaccine which:

  • Demonstrated improved viral clearance and reduced histopathology in an RSV mouse challenge model.
  • Resulted in viral clearance from the lung associated with Th17 generation that is highly correlated with lower airway hyper-reactivity (AHR).
  • Generated robust immune responses that are protective against a heterologous A2 challenge in cotton rats.

NanoBio's RSV vaccine uses nanoemulsion technology as an intranasal adjuvant and delivery system derived from its clinically-validated NanoStat® technology platform.

Source: NanoBio Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Researchers develop a multivalent vaccine for COVID-19 and influenza